Newsletter  |  February 2015  
REDEFINING QUALITY - Full Service Provider Focused on Early Stage Clinical Research

Evaluating Drug Effects on the Ability to Operate a Motor Vehicle

Last month, the long awaited guidance detailing the FDA's current thinking and expectations around how and when to assess a new drug's ability to affect driving was released in draft form. The ability of Algorithme Pharma to conduct these specialized tests, combined with the highly recognized battery of psychomotor and neurocognitive tests offered by CRC, will allow us to seamlessly incorporate key elements of the guidance into our trials.

Read more  >>

Algorithme Pharma USA
Algorithme Pharma USA has its First Studies Underway

Last October, Altasciences expanded into the United States with the opening of Algorithme Pharma USA, in Fargo, North Dakota. Today, we are pleased to announce that our first studies were initiated and completed in January, just 91 days from the US contract being signed, and despite the holiday hustle.

Read the Press Release  >>

Bioanalysis by LCMS: A Single Reagent-Free Method

Dr. Jonathan St-Germain, Senior Scientist, Large Molecule Method Development, Algorithme Pharma, will be present on March 4, at 10 a.m. EDT.

See more details and to register  >>

ASCPT 2015 Annual Meeting

Meet Laura Sayegh, Clinical Research Scientist, Algorithme Pharma, as she presents two posters on March 5, from 4:30 p.m. to 6:30 p.m.:


Fed and fasted comparative bioavailability study of RHB-102 (once-daily Ondansetron 24 mg extended-release tablets) in healthy volunteers



Request a meeting  >>

Comparative bioavailability study of RHB-102 (Ondansetron 24 mg ER tablets QD) vs. Ondansetron 8 mg tablets bid and a single dose of Ondansetron 24 mg in healthy volunteers



Request a meeting  >>
FDA Draft Guidance on Dr OZ

See our three-part series in the Bioanalysis Journal

2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis

Part 1 - small molecules

Bioanalysis, 2014, 6 (22), Pages 3039-3049

Part 2 - hybrid LBA/LCMS, ELN & regulatory agencies' input

Bioanalysis, 2014, 6 (23), Pages 3237-3249

Part 3 - LBA and immunogenicity

Bioanalysis, 2014, 6 (24), Pages 3355-3368


Request to
Meet Us

ASCPT Annual Meeting

March 3-7
New Orleans, LA

DCAT Week '15

March 16-19
New York, NY

Society of Toxicology Annual Meeting

March 22-26,
San Diego, CA

MassBio 2015 Annual Meeting

March 26-27,
Cambridge, MA

For more information, please contact us:
450 973-6077 | 888 267-7449 | contact@algopharm.com
©2015 All Rights Reserved, Algorithme Pharma inc.